AU2016354661B2 - Substituted tricyclic 1,4-benzodiazepinone derivatives as allosteric modulators of group II metabotropic glutamate receptors - Google Patents

Substituted tricyclic 1,4-benzodiazepinone derivatives as allosteric modulators of group II metabotropic glutamate receptors Download PDF

Info

Publication number
AU2016354661B2
AU2016354661B2 AU2016354661A AU2016354661A AU2016354661B2 AU 2016354661 B2 AU2016354661 B2 AU 2016354661B2 AU 2016354661 A AU2016354661 A AU 2016354661A AU 2016354661 A AU2016354661 A AU 2016354661A AU 2016354661 B2 AU2016354661 B2 AU 2016354661B2
Authority
AU
Australia
Prior art keywords
alkyl
methyl
benzo
diazepine
cyclopropan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2016354661A
Other languages
English (en)
Other versions
AU2016354661A1 (en
Inventor
Baptiste Manteau
Stanislas Mayer
Stephan Schann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Domain Therapeutics SA
Original Assignee
Domain Therapeutics SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Domain Therapeutics SA filed Critical Domain Therapeutics SA
Publication of AU2016354661A1 publication Critical patent/AU2016354661A1/en
Application granted granted Critical
Publication of AU2016354661B2 publication Critical patent/AU2016354661B2/en
Assigned to DOMAIN THERAPEUTICS reassignment DOMAIN THERAPEUTICS Request for Assignment Assignors: MAVALON THERAPEUTICS LIMITED
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
AU2016354661A 2015-11-13 2016-11-11 Substituted tricyclic 1,4-benzodiazepinone derivatives as allosteric modulators of group II metabotropic glutamate receptors Ceased AU2016354661B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15194611 2015-11-13
EP15194611.8 2015-11-13
PCT/GB2016/053550 WO2017081483A1 (en) 2015-11-13 2016-11-11 Substituted tricyclic 1,4-benzodiazepinone derivatives as allosteric modulators of group ii metabotropic glutamate receptors

Publications (2)

Publication Number Publication Date
AU2016354661A1 AU2016354661A1 (en) 2018-06-07
AU2016354661B2 true AU2016354661B2 (en) 2020-12-10

Family

ID=54542126

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016354661A Ceased AU2016354661B2 (en) 2015-11-13 2016-11-11 Substituted tricyclic 1,4-benzodiazepinone derivatives as allosteric modulators of group II metabotropic glutamate receptors

Country Status (10)

Country Link
US (1) US11008323B2 (enExample)
EP (1) EP3374360A1 (enExample)
JP (1) JP7100362B2 (enExample)
KR (1) KR20180097542A (enExample)
CN (1) CN108834415B (enExample)
AU (1) AU2016354661B2 (enExample)
BR (1) BR112018009550A2 (enExample)
CA (1) CA3004680A1 (enExample)
IL (1) IL259214B (enExample)
WO (1) WO2017081483A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110769830A (zh) * 2017-05-12 2020-02-07 马瓦隆治疗有限公司 作为ii组代谢型谷氨酸受体的别构调节剂的取代的杂环化合物
CN108084187A (zh) * 2017-12-15 2018-05-29 宜昌人福药业有限责任公司 苯并二氮杂*类氢化物
CN108003164A (zh) * 2017-12-15 2018-05-08 宜昌人福药业有限责任公司 苯并二氮杂*类化合物
WO2020223701A1 (en) * 2019-05-02 2020-11-05 The Broad Institute, Inc. Methods for treating neurodevelopmental disorders
CN110172068A (zh) * 2019-06-05 2019-08-27 河南龙湖生物技术有限公司 具有抗肿瘤活性的苯并噻唑类化合物及其制备方法和应用
WO2021226208A2 (en) 2020-05-05 2021-11-11 Nuvalent, Inc. Heteroaromatic macrocyclic ether chemotherapeutic agents
KR102698413B1 (ko) 2020-05-05 2024-08-26 뉴베일런트, 아이엔씨. 헤테로방향족 거대환식 에터 화학치료제
TW202320768A (zh) 2021-10-01 2023-06-01 美商努法倫特公司 雜芳族大環醚化合物之固體形式、醫藥組成物及製備
WO2026006700A1 (en) * 2024-06-28 2026-01-02 Regents Of The University Of Michigan Pyrrolo[1,2-a]-azocine analogues as iap antagonists
CN118993997A (zh) * 2024-10-23 2024-11-22 浙江雅辰药物科技股份有限公司 一种3-溴-2-苯基吡啶的制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4130716A (en) 1977-03-07 1978-12-19 Hoffmann-La Roche Inc. Pyrazolo benzodiazepines
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
DE3169595D1 (en) 1980-11-10 1985-05-02 Gersonde Klaus Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3486459D1 (de) 1983-09-26 1997-12-11 Udo Dr Med Ehrenfeld Mittel und Erzeugnis für die Diagnose und Therapie von Tumoren sowie zur Behandlung von Schwächen der zelligen und humoralen Immunabwehr
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
FI880814A7 (fi) 1987-03-10 1988-09-11 Hoffmann La Roche Imidazodiazepin-derivat.
MX2009007053A (es) 2006-12-28 2009-07-09 Abbott Lab Inhibidores de poli (adp-ribosa) polimerasa.
US10059671B2 (en) 2013-02-04 2018-08-28 Prexton Therapeutics Sa Positive allosteric modulators of mGluR3

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LUCIA BERTELLI ET AL, "1,2,3-Triazolo[1,5-a][1,4]- and 1,2,3-triazolo[1,5-a][1,5]benzodiazepine derivatives: Synthesis and benzodiazepine receptor binding", IL FARMACO, FR, (1998), vol. 53, no. 4, pages 305 - 311 *

Also Published As

Publication number Publication date
US20180346468A1 (en) 2018-12-06
JP2019504108A (ja) 2019-02-14
BR112018009550A2 (pt) 2018-11-06
EP3374360A1 (en) 2018-09-19
JP7100362B2 (ja) 2022-07-13
IL259214B (en) 2021-09-30
CA3004680A1 (en) 2017-05-18
CN108834415B (zh) 2021-12-24
IL259214A (en) 2018-07-31
AU2016354661A1 (en) 2018-06-07
KR20180097542A (ko) 2018-08-31
US11008323B2 (en) 2021-05-18
WO2017081483A1 (en) 2017-05-18
CN108834415A (zh) 2018-11-16

Similar Documents

Publication Publication Date Title
US11008323B2 (en) Substituted tricyclic 1,4-benzodiazepinone derivatives as allosteric modulators of group II metabotropic glutamate receptors
RS61919B1 (sr) Inhibitori hpk1 i postupci za njihovo korišćenje
CA2890876A1 (en) N-pyrrolidinyl, n'-pyrazolyl- urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
BR112016024472B1 (pt) Composto, medicamento, e, uso de um composto
IL194832A (en) History of pyridopyrazine and pharmaceutical preparations
JP6860551B2 (ja) 芳香環化合物
WO2015190564A1 (ja) 含窒素複素環化合物
JP6751161B2 (ja) フッ素含有トリアゾロピリジン系化合物、その製造方法、医薬組成物及び用途
JP2021519316A (ja) Ｔｌｒ２シグナル伝達の調節剤としての化合物
JP5455130B2 (ja) 複素環式誘導体
JP2014514315A (ja) ピラゾリジン−３−オン誘導体
CN111936495A (zh) 杂环化合物及其用途
WO2014181813A1 (ja) 複素環化合物
AU2019351469B2 (en) Heterocyclic compound
TW202024020A (zh) 治療神經退化性疾病之方法
US11472806B2 (en) Substituted heterocyclic compounds as allosteric modulators of group II metabotropic glutamate receptors
US20190152979A1 (en) Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group ii metabotropic glutamate receptors
AU2018289939B2 (en) Heterocyclic compound
WO2024120519A1 (zh) Tead抑制剂、其制备方法和在医学上的应用

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: DOMAIN THERAPEUTICS

Free format text: FORMER APPLICANT(S): MAVALON THERAPEUTICS LIMITED

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired